KEY POINTS
- Abbott shares jumped about 11% after beating expectations and raising its profit forecast for the year.
- Sales rose 13% to US$12.6 billion, with growth coming from several parts of the business, not just one.
- The stock stood out on a day when AI chip stocks were falling, as investors looked for steadier names.
- Our view: a clean, high-quality result, and the big jump shows how much investors value dependable growth right now.
Abbott (NYSE:ABT) shares soared around 11% on Thursday, one of the healthcare giant’s biggest one-day moves in years. The company beat expectations on both sales and profit, then did the thing investors like most: it raised its forecast for the rest of the year. On a day when AI chip stocks were sinking, Abbott’s steady growth stood out.
What Abbott Reported
The results were strong across the board. Sales rose 13% to US$12.6 billion, ahead of what analysts expected, and profit also came in above forecasts.
Importantly, the growth was broad. Medical devices, its heart and diabetes-care products, and its international drug business all grew solidly. Diagnostics jumped too, helped by Abbott’s recent purchase of cancer-testing company Exact Sciences.
The only weak spot was nutrition, where sales dipped slightly. But even that business improved from the previous quarter, so the trend is heading the right way.
- Updated
- INSIDER CONVICTION TRADES FY26
The market hasn't noticed yet.
Disclosed by law. Missed by most investors. 129 trades tracked by us.
NO Credit card
- Director buys & sells tracked
- Buy / Hold / Sell verdict on every stock
- Technical analysis included
The Raised Forecast Is What Mattered Most
Beating one quarter’s numbers is good. Telling investors the rest of the year will be even better is what really moves a stock.
Abbott lifted its full-year profit forecast, and the new range sits above what Wall Street had expected. CEO Robert Ford said the company is entering the second half of the year with “momentum building across the portfolio.” In plain terms, Abbott is saying its growth is speeding up, not slowing down. That confidence is what sent the shares higher.
What It Means for Investors
Abbott is not a flashy stock, and that is exactly the point. It makes medical devices, diagnostic tests, medicines and nutrition products, and it has now paid a dividend for 410 quarters in a row. That kind of consistency is rare.
This quarter showed why investors like the business. The growth did not depend on any single product; the company kept returning cash to shareholders, and management was confident enough to raise its outlook. There was very little to pick holes in.
The timing helped too. Thursday was a rough day for AI chip stocks, which fell hard on profit-taking and worries about high valuations. Against that background, a dependable healthcare company beating expectations looked especially appealing. When the riskier parts of the market wobble, money often moves toward steadier names, and Abbott was a clear winner.
Our take: this was a genuinely strong, well-rounded quarter, and the 11% jump reflects both the result and the mood of the day. Abbott will never deliver the explosive gains of an AI chipmaker. But for investors who want steady growth, a rising dividend and a business that holds up in almost any environment, this was a reminder of why the stock sits in so many portfolios. The main thing to watch now is whether the faster growth Abbott is promising for the second half actually arrives.
